Please login to the form below

Not currently logged in

Covance takes over abandoned Eli Lilly site

US pharmaceutical developer Covance buys Lilly's partially constructed facility to develop a Class A drug development laboratory

US pharmaceutical developer Covance has acquired Eli Lilly's partially constructed facility in the US state of Virginia to develop a Class A drug development laboratory.

Lilly began work on the USD 325m property for insulin manufacturing in 2006, but then abandoned construction halfway through in January 2007, citing changes in its global manufacturing strategy. The company returned approximately USD 5m in economic development incentives it received from the state to construct the 2.8-hectare site.

Covance will invest USD 175m in the project, which includes expanding the facility to about four hectares. It will relocate 450 employees to the property by 2011 from existing operations in Virginia and said it may hire an additional 100 employees by 2014.

Covance will also receive about USD 3.7m in state incentives.

30th September 2008


Featured jobs

Subscribe to our email news alerts


Add my company
3 Monkeys Zeno

3 Monkeys Zeno is the UK arm of Zeno Group, a global integrated communications consultancy. Everything we do is rooted...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...